PharmaShots | Incisive News in 3 Shots

Subscribe Now

All Posts by Date

Apellis and Beam Sign a Five-Year Research Collaboration to Discover Novel Therapies for Complement-Driven Diseases

Apellis and Beam Sign a Five-Year Research Collaboration to Discover Novel Therapies for Complement-Driven Diseases

July 1, 2021

STADA and Xbrane's Xlucane (biosimilar- ranibizumab) Meet its Primary Endpoint in P-III Xplore Study

STADA and Xbrane's Xlucane (biosimilar- ranibizumab) Meet its Primary Endpoint in P-III Xplore Study

July 1, 2021

LEXEO Therapeutics' LX2006 Receives the US FDA's Rare Pediatric Disease Designation and Orphan Drug Designation to Treat Friedreich Ataxia

LEXEO Therapeutics' LX2006 Receives the US FDA's Rare Pediatric Disease Designation and Orphan Drug Designation to Treat Friedreic...

July 1, 2021

Abbott's XIENCE Stent Receives the US FDA's Approval for Shortest Blood Thinner Course in Patients with High Bleeding Risk

Abbott's XIENCE Stent Receives the US FDA's Approval for Shortest Blood Thinner Course in Patients with High Bleeding Risk

July 1, 2021

Jazz's Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) Receives the US FDA's Approval for Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Jazz's Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) Receives the US FDA's Approval for Acute Lymphoblastic Leukem...

July 1, 2021

Orchard Collaborates with Pharming to Develop and Commercialize OTL-105 for Hereditary Angioedema

Orchard Collaborates with Pharming to Develop and Commercialize OTL-105 for Hereditary Angioedema

July 1, 2021

Contact Us

First Floor, B 150, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
[email protected]
Newsletter

Our Information

Follow Us